NCT05805891View on ClinicalTrials.gov

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

NARecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Rheumatoid Arthritis

Interventions

DRUG

bortezomib

bortezomib 2mg/week subcutaneous injection

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Chinese SLE Treatment And Research Group

OTHER